GeneDx Holdings Corp. (NASDAQ:WGS) Given Average Rating of “Moderate Buy” by Analysts

GeneDx Holdings Corp. (NASDAQ:WGS) has been assigned an average recommendation of “Moderate Buy” from the ten research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $138.1250.

Several analysts have weighed in on WGS shares. Guggenheim reaffirmed a “buy” rating and set a $170.00 price objective (up from $115.00) on shares of GeneDx in a research note on Wednesday, October 29th. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a research report on Wednesday, January 21st. BTIG Research lifted their price objective on GeneDx from $165.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Wall Street Zen lowered GeneDx from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Wells Fargo & Company set a $155.00 target price on GeneDx and gave the company an “equal weight” rating in a research note on Monday, December 15th.

Insider Activity at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 1,653 shares of the business’s stock in a transaction dated Thursday, January 29th. The shares were sold at an average price of $94.00, for a total value of $155,382.00. Following the completion of the transaction, the chief executive officer directly owned 16,458 shares of the company’s stock, valued at approximately $1,547,052. The trade was a 9.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Bryan Dechairo sold 5,961 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $85.70, for a total transaction of $510,857.70. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 68,961 shares of company stock worth $10,027,891. 29.60% of the stock is owned by insiders.

Institutional Investors Weigh In On GeneDx

A number of institutional investors and hedge funds have recently made changes to their positions in WGS. Jones Financial Companies Lllp boosted its holdings in GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after acquiring an additional 186 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of GeneDx in the 4th quarter valued at about $35,000. Quarry LP grew its position in shares of GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after buying an additional 209 shares during the period. Gordian Capital Singapore Pte Ltd bought a new stake in shares of GeneDx during the third quarter worth approximately $65,000. Finally, AlphaQuest LLC raised its stake in shares of GeneDx by 351.5% during the second quarter. AlphaQuest LLC now owns 763 shares of the company’s stock worth $70,000 after buying an additional 594 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

GeneDx Trading Up 0.2%

Shares of GeneDx stock opened at $84.29 on Tuesday. GeneDx has a 12-month low of $55.17 and a 12-month high of $170.87. The stock has a market capitalization of $2.44 billion, a P/E ratio of 936.56 and a beta of 2.00. The company has a 50-day simple moving average of $126.14 and a 200 day simple moving average of $124.92. The company has a quick ratio of 2.59, a current ratio of 2.71 and a debt-to-equity ratio of 0.18.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.